地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18771149750
传真:15172431432
邮箱:sales@amyjet.com

艾美捷科技代理BBI Solutions品牌诊断原料。
BBI Solutions的产品范围广泛,包括人的抗原、抗体、血清、血浆和临床化学酶等优质原料,还生产世界知名的ELISA试剂盒、生物传感器的标签、黄金纳米粒子和葡萄糖氧化酶等。BBI Solutions提供一系列专业的服务,包括抗体开发、抗体制造、抗原定制、金共轭化等。其独特的抗体开发、侧向流动试验开发和制造服务组合,能够支持客户从概念到商业化的全过程。BBI Solutions拥有专业的研究团队和完善的生产和质控流程,确保了公司产品的高品质。其提供的技术支持涵盖了产品的应用验证、配对使用抗体的推荐等方面,为客户提供了全方位的技术保障。BBI Solutions公司提供试剂专用酶:辣根过氧化物酶、谷氨酸脱氢酶、碱性磷酸酶、尿素酶、胆固醇酯酶,聚链霉亲和素,人源蛋白,单克隆抗体,金纳米颗粒等。
<<< " data-original="http://panagene.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理BBI Solutions品牌诊断原料"> 艾美捷科技代理BBI Solutions品牌诊断原料
<艾美捷科技代理RA Biosources品牌全系列产品
RA Biosources,Inc.是由郭博士于2003年1月在美国加利福尼亚州贝尔蒙特创立的一家生物技术公司,专注于开发作为体外诊断试剂的单克隆抗体。经过多年的发展,RA Biosources公司产品线包括癌症标志物、滥用药物、传染源、胶原蛋白和细胞外基质蛋白、激素以及血清蛋白等。这显示了公司在生物技术研发方面的深厚实力和广泛覆盖。

▍RA Biosources部分产品列表
| 货号 | 同种型 | 品名 | 产品描述 |
| MA011 | IgG1 | Monoclonal Anti-human Alpha Fetoprotein (AFP) | This antibody reacts with AFP. There is no cross reactivity with human albumin, CEA, ferritin, hCG and PSA |
| MB034 | IgG1 | B2 Microglobulin | This antibody is specific to human beta-2 microglobulin |
| MC091 | IgG1 | Monoclonal Anti-CA12-5 | This antibody reacts with CA12-5 |
| MC123 | IgG1 | Monoclonal Anti-CA72-4 | This antibody reacts with CA72-4 |
| MC021 | IgG1 | Monoclonal Anti-human Carcinoembryonic Antigen (CEA) | This antibody reacts with CEA. There is no cross reactivity with human NCA, hCG and PSA |
| MF016 | IgG1 | Monoclonal Anti-human Ferritin | This antibody reacts with human ferritin |
| MG021 | IgG1 | Monoclonal Anti-human Growth Hormone (HGH) | This antibody reacts with human growth hormone |
| MP081 | IgG1 | Monoclonal Anti-Prostate Acid Phosphatase (PAP) | Specific to PAP |
| MP015 | IgG1 | Monoclonal Anti-human Prostate Specific Antigen (PSA) | This antibody reacts with free PSA and PSA-ACT (PSA-alpha 1-antichymotrypsin) complex. There is no cross reactivity with human kallikrein and ACT |
| MP016 | IgG1 | Monoclonal Anti-human PSA-ACT | This antibody reacts with PSA-ACT. There is no cross reactivity with free PSA and ACT |
| MP014 | IgG1 | Monoclonal Anti-human Free Prostate Specific Antigen (fPSA) | This antibody reacts only with free PSA. There is no cross reactivity with PSA-ACT, human kallikrein, or ACT |
| MC035 | IgG2a | Monoclonal Anti-Human Collagen Type IV | This antibody is specific to human collagen type IV |
| ML021 | IgG1 | human laminin | This antibody is specific to human laminin. It does not react with mouse laminin. |
| MF023 | IgG1 | Monoclonal Anti-Human Fibronectin | This antibody is specific to human fibronectin |
| ML031 | IgG1 | Monoclonal Anti-Mouse Laminin | This antibody is specific to mouse laminin. It does not react with human laminin. |
| MM102 | IgG1 | Monoclonal 6-Monoacetylmorphine (6MAM) | Mab to 6MAM |
| MA041 | IgG1 | Monoclonal AB-Pinaca | Mab to AB-Pinaca |
| MA022 | IgG2b | Monoclonal Anti-Amphetamine | Mab to amphetamine |
| MB011 | IgG1 | Monoclonal Anti-Barbiturates | Mab to barbiturates |
| MB021 | IgG1 | Monoclonal Anti-Benzoylecgonine | This antibody reacts with benzoylecgonine |
| MC082 | IgG1 | Monoclonal Anti-Clonazepam | This antibody reacts with clonazepam and 7-clonazepam |
| MC011 | IgG1 | Monoclonal Anti-Cotinine | Specific to cotinine |
| ME012 | IgG1 | Monoclonal Anti-EDDP | This antibody reacts with EDDP |
| MF041 | IgG1 | Monoclonal Anti-Fentanyl | Mab to fentanyl |
| MK015 | IgG1 | Monoclonal Anti-K2 | Mab to K2 |
| MK021 | IgG2b | Monoclonal Anti-Ketamine | Mab to ketamine |
| ML041 | IgG1 | Monoclonal Anti-Lysergic acid diethylamide (LSD) | Mab to LSD |
| MM091 | IgG1 | Monoclonal Anti-Melatonin | Mab to Melatonin |
| MM011 | IgG1 | Monoclonal Anti-Methadone | This antibody reacts with methadone |
| MM031 | IgG1 | Monoclonal Anti-Methylenedioxymethamphetamine (MDMA) | Mab to MDMA |
| MM063 | IgG1 | Monoclonal Anti-Methamphetamine | Mab to methamphetamine |
| MM111 | IgG1 | Monoclonal Anti-Methaqualone | This antibody reacts with methaqualone |
| MM071 | IgG2a | Monoclonal Anti-Methcathinone | Mab to methcathinone |
| MM083 | IgG1 | Monoclonal Anti-Methotrexate | Mab to methotrexate |
| MM041 | IgG1 | Monoclonal Anti-Morphine | This antibody reacts with morphine |
| MO022 | IgG1 | Monoclonal Anti-Oxycodone | This antibody reacts with oxycodone |
<艾美捷科技代理Clearsynth品牌全系列产品
Clearsynth研发中心位于海得拉巴,以“创新与精准之心”为核心理念,打造了一个精心设计的空间,旨在激发突破性的发现并提升可能性的界限。专注于创新有机化学和独特复杂分子的合成,涵盖稳定同位素标记化合物、代谢物、杂质、葡萄糖醛酸、手性化合物、共轭物杂质和放射性标记化合物等。承接复杂分子或“难以合成”的合成化合物/中间体的定制合成服务。提供超过3,59,000个高纯度参考标准品,Clearsynth公司的产品线包括稳定同位素、原料药、杂质、亚硝胺、二级标准、散装化合物等。

▍Clearsynth服务领域
● 小分子:合成各种精细化学品和化合物,用于从毫克到数公斤规模的小分子药物发现。
● 工艺开发:开发新的合成路线,也可以修改和优化客户提供的工艺。
● 合同研发综合:专注于从临床前阶段到III期以及成功的技术转让。
● 生物核磁共振服务:位于海得拉巴的符合GLP标准的高场生物核磁共振/600MHz和300MHz设施,由敬业且经验丰富的核磁共振操作员提供支持。
● CDMO服务:致力于复杂、危险和可持续的产品和工艺。
● 分析服务:符合FDA、BIS、卫生部和其他标准机构制定的所有监管规范。
▍Clearsynth部分产品列表
| 品名 | 货号 | CAS号 |
| α-Keto Isovaleric Acid Sodium Salt 13C D6 | CS-R-00562 | 3715-29-5 (Unlabeled) |
| α-Keto Isovaleric Acid Sodium Salt 13C5 | CS-R-00482 | 1173018-24-0 |
| α-Keto Isovaleric Acid Sodium Salt D6 | CS-R-00485 | 3715-29-5(Unlabeled) |
| α-Keto Isovaleric Acid Sodium Salt Dimethyl-13C2 | CS-R-00488 | 634908-42-2 |
| α-KETOBUTYRIC ACID, SODIUM 13C, D4 | CS-R-00475 | 2013-26-5 (Unlabeled) |
| α-KETOBUTYRIC ACID, SODIUM SALT 13C4, D2 | CS-R-00477 | 360769-17-1 |
| α-KETOBUTYRIC ACID, SODIUM SALT METHYL-13C | CS-R-00478 | 634908-43-3 |
| α-KETOBUTYRIC ACID, SODIUM SALT METHYL-13C, D2 | CS-R-00479 | 1007476-77-8 |
| α-Ketobutyric Acid-d2 Sodium Salt | CS-T-30294 | 1007476-82-5 |
| α-Ketoglutaric acid 13C2, D2 | CS-CX-00331 | 123953-28-6 |
| α-KETOGLUTARIC ACID 13C5 | CS-R-00549 | 161096-83-9 |
| α-KETOGLUTARIC ACID, DISODIUM SALT 13C4 | CS-R-00480 | 1429051-79-5 |
| α-KETOISOCAPROIC ACID 13C | CS-R-00551 | 92751-19-4 |
| α-KETOISOCAPROIC ACID, SODIUM SALT 13C2 | CS-R-00552 | 4502-00-5(Unlabeled) |
| α-KETOISOCAPROIC ACID, SODIUM SALT ISOPROPYL-D7 | CS-R-00555 | 1795020-84-6 |
| α-Tocopherol-[13C3] | CS-I-00340 | 59-02-9 (Unlabeled) |
| β-ALANINE 13C | CS-R-00042 | 65138-34-3 |
| β-ALANINE 13C, 15N | CS-R-00449 | 1822942-84-6 |
| β-ALANINE 13C3 | CS-R-00040 | 107-95-9 (Unlabeled) |
| β-ALANINE 15N | CS-R-00041 | 204451-53-6 |
| β-CAROTENE 13C4 | CS-R-00567 | 7235-40-7(Unlabeled) |
| -β-Cyclocitral-d5 | CS-T-51410 | 78995-98-9 |
| β-Endosulfan D4 | CS-O-15034 | 203716-99-8 |
| β-Ionone-[13C3] | CS-I-00368 | 14901-07-6 (Unlabeled) |
| βmethasone 17-propionate-d3 | CS-O-10426 | 5534-13-4 (Unlabeled) |
| β-Tocopherol-[13C9] | CS-I-00341 | 59-02-9 (Unlabeled) |
| γ-HCH D6 | CS-EJ-0009 | 60556-82-3 |
| (-)-(2S,3S)-Viridifloric Acid Acetonide-d7 | CS-T-102816 | 95462-09-2(Unlabelled) |
| (-)-(2S,3S)-Viridifloric Acid Ethyl Ester-d7 | CS-T-102815 | 176712-53-1(Unlabelled) |
| (-)-(3S)-3-Hydroxy Quinine-vinyl-d3 | CS-T-101262 | 2734920-65-9 |
| (-)-(S)-Cibenzoline-D4 | CS-O-33254 | 103419-18-7 (Unlabeled) |
| (-)-2-Amino-6-propionamido-d3-tetrahydrobenzothiazole | CS-T-97805 | 1217644-20-6 |
| (-)-2-Methyl Isoborneol-d3 | CS-T-58298 | 135441-89-3 |
| (-)-alfa-Benidipine-d5 Hydrochloride | CS-P-07295 | 129262-07-3 (Unlabeled) |
| (-)-Cannabidiol-d9 | CS-TA-86322 | 1246819-21-5 |
| (-)-Citrinin-13C,d2 | CS-T-72877 | 1329611-85-9 |
<艾美捷科技代理Independent Forensics品牌全系列产品
Independent Forensics 是一家法医 DNA 实验室,提供 DNA 测试,致力于为犯罪实验室、医学遗传学和人类个体识别领域开发新颖、创新且可靠的产品和服务。IFI的研究与开发涵盖面向执法机构的新产品、用于高灵敏度遗传识别的先进技术,以及面向健康专业人士和公众的新型基因检测方法。

▍Independent Forensics产品线
● AMPLICON RX™ KITS:DNA-STR多重检测扩增后回收技术;
● 显微镜套装:专为手动或自动化精子搜寻与细胞分离定制的蔡司显微镜及成像系统,并包含SPERM HY-LITER™ 精细胞检测试剂盒。
● iPLEX STR 检测试剂盒:用于18个STR基因座及Amelogenin基因检测的多重STR试剂盒。
● ONE TOUCH™ 试剂盒:适用于:接触DNA、指纹、粘性介质及激光捕获显微切割样本。
● 快速斑迹识别试剂盒:RSID™系列专为快速、简便、可靠地检测法医实验室遇到的各种样本中的特定人体体液而设计。
● SPERM HY-LITER™ 精细胞检测试剂盒:专为性侵证据设计的完整荧光染色试剂盒。特异性强。灵敏度高。操作灵活。支持自动化。
▍Independent Forensics部分产品列表
| 分类 | 货号 | 产品描述 |
| AMPLICON™ Rx 试剂盒 | 5999 | Amplicon Rx™ 10 检测/试剂盒 - 1/2 尺寸试剂盒 |
| AMPLICON™ Rx 试剂盒 | 6000 | Amplicon Rx™ 20 检测试剂盒/试剂盒 |
| AMPLICON™ Rx 试剂盒 | 6001 | Amplicon Rx™ 40 检测试剂盒/试剂盒 - 大试剂盒 |
| iPlex STR™ | 6600 | 96 次反应 |
| iPlex STR™ | 6500 | 48 次反应 |
| iPlex STR™ | 6400 | 24 次反应 |
| iPlex STR™ | 6600-310 | 310 基质标准品 |
| iPlex STR™ | 6600-3100 | 其他尺寸标准 |
| iPlex STR™ | 6600-3130 | 其他尺寸标准 |
| iPlex STR™ | 6600-3500 | 其他尺寸标准 |
| iPlex STR™ | 6600-S400 | 其他尺寸标准 |
| iPlex STR™ | 6700-M1 | iPLEX-STR™ 迷你 1 |
| iPlex STR™ | 6700-M2 | iPLEX-STR™ 迷你 2 |
| iPlex STR™ | 6800-Y | iPLEX-STR™ Y |
| ONE TOUCH™ DNA Rescue Adhesives Kits | 7002-LIFT | 一键式 DNA 免费提升卡 - 15 个/包 |
| ONE TOUCH™ DNA Rescue Adhesives Kits | 7002-CK | 一键式采集现场试剂盒 - 20 个无 DNA 拭子 + NDLB 采集缓冲液 |
| RSID™ Saliva Lab Kits | 0130 | 通用缓冲液 25 次测试/试剂盒 |
| RSID™ Saliva Lab Kits | 0130-LARGE | RSID SALIVA UNIVERSAL BUFFER 40 次检测/试剂盒 |
| RSID™ Saliva Lab Kits | 0100 | 双缓冲液 25 次检测/试剂盒 |
| RSID™ Semen Field Kits | 2000-SMALL | 5 份检测试剂盒/试剂盒(小号 - 不包括剪刀和证据信封) |
| RSID™ Semen Field Kits | 2000 | 5 包/套件(用于现场的完整套件) |
| RSID™ Semen Field Kits | Oct-00 | 10 个测试/套件(小版 - 不包括剪刀和证据信封) |
| RSID™ Semen Lab Kits | 0230 | 通用缓冲液 25 次测试/试剂盒 |
| RSID™ Semen Lab Kits | 0230-LARGE | RSID SEMEN UNIVERSAL BUFFER 40 次检测/试剂盒 |
| RSID™ Semen Lab Kits | 0200 | 双缓冲液 25 次检测/试剂盒 |
| RSID™ Urine Lab Kits | 0400-05 | 5 次检测/试剂盒,含缓冲液 |
| RSID™ Urine Lab Kits | 0400-10 | 10 次检测/试剂盒,含缓冲液 |
| Sperm Hyliter™ Replacement & Accessories | 8000 | SPERM HY-LITER™ 疏水笔,用于勾勒涂片载玻片的轮廓 |
| Sperm Hyliter™ Replacement & Accessories | 8005 | 用于医院涂片载玻片的垫圈,矩形载玻片架,12 个/包 |
| Sperm Hyliter™ Replacement & Accessories | 8010 | 精子 HY-L™ 染色阳性对照玻片(指定 HY-LITER、EXPRESS 或 PI 染色) |
| Sperm Hyliter™ Replacement & Accessories | 8020 | SPERM HY-LITER™ 洗涤缓冲液 |
| Sperm Hyliter™ Replacement & Accessories | 8030 | SPERM HY-LITER™ 封片剂 |
| Sperm Hyliter™ Replacement & Accessories | 8040 | SPERM HY-LITER™ 固定剂 |
| Sperm Hyliter™ Replacement & Accessories | 8050 | 现成的 DTT 100 x 110 μL 一次性等分试样,1.0 M 储备液 pH 8.0 DTT |
| Sperm Hyliter™ Replacement & Accessories | 8050-INT | 现成的 DTT 100 x 110 μL 一次性等分试样,1.0 M 储备液 pH 8.0 DTT - 国际运输 |
| Sperm Hyliter™ Express | 7301-MINI | Mini SPERM HY-LITER™ 试剂,用于染色 13、11 mm 孔或 26、8 mm 孔 |
| Sperm Hyliter™ Express | 7301 | 用于染色 26、11 mm 孔或 50、8 mm 孔的小精子 HY-LITER™ 试剂 |
| Sperm Hyliter™ Express | 7302 | 中等精子 HY-LITTER™ 试剂,用于染色 50, 11 mm 孔或 100, 8 mm 孔 |
| Sperm Hyliter™ Express | 7303 | 大精子 HY-LITER™ 试剂,用于染色 150、11 mm 孔或 300、8 mm 孔 |
| Sperm Hyliter™ Express | 7302-SOS | SPERM HY-LITER™ SOS - 带国际 DTT 的新型溶液染色试剂盒,染色 50 载玻片 |
| Sperm Hyliter™ Express | 7303P | SPERM HY-LITER™ EXPRESS 大号套件,带 DTT,可选择载玻片和储物盒 |
| Sperm Hyliter™ Microscopes | 10078 | SPERMCAM - 2/3“ CCD 彩色相机,带 SpermCapture 软件,需要支持 C 接口的显微镜 |
| Sperm Hyliter™ Microscopes | 27777 | SPERM HY-LITER™ aureka 细胞分离系统,带染色试剂盒包和现场培训 |
| Sperm Hyliter™ Microscopes | 37777 | SPERM HY-LITER™ LCM 精子搜索、解剖系统与染色套件包和现场培训 |
| Sperm Hyliter™ Microscopes | custom | 提供替换显微镜部件和附件 - 物镜、灯泡、电线、橡胶目镜杯、防尘罩等。 |
| Sperm Hyliter™ Microscope Slides | 9108-25 | 精子 HY-L™ 1 x 8 毫米,25 张载玻片/包 |
| Sperm Hyliter™ Microscope Slides | 9108-26 | SPERM HY-LITER™ 1 x 8 mm, 25 张载玻片/包 & 存储盒 |
| Sperm Hyliter™ Microscope Slides | 9111-25 | 精子 HY-LITER™ 1 x 11 毫米,25 张载玻片/包 |
| Sperm Hyliter™ Microscope Slides | 9111-26 | SPERM HY-LITER™ 1 x 11毫米,25张幻灯片/包和储存盒 |
| Sperm Hyliter™ Microscope Slides | 9211-25 | 精子 HY-LITER™ 2 x 11 毫米,25 张载玻片/包 |
| Sperm Hyliter™ Microscope Slides | 9211-26 | SPERM HY-LITER™ 2 x 11 mm, 25张载玻片/包&存储盒 |
| Sperm Hyliter™ Microscope Slides | 9408-25 | 精子 HY-L™ 4 x 8 毫米,25 张玻片/包 |
| Sperm Hyliter™ Microscope Slides | 9408-26 | SPERM HY-LITER™ 4 x 8 mm,25 张载玻片/包和储存盒 |
| Sperm Hyliter™ Microscope Slides | 9000-25 | 精子 HY-LITER™ 24 x 60 毫米,25 张载玻片/包 |
| Sperm Hyliter™ Microscope Slides | 9000-26 | SPERM HY-LITER™ 24 x 60 mm, 25张载玻片/包&储存盒 |
| Sperm Hyliter™ Microscope Slides | 9999-00 | SPERM HY-LITER™ 定制设计的显微镜载玻片 |
| Sperm Hyliter™ PI | 7401 | 用于染色 26、11 mm 孔或 50、8 mm 孔的小精子 HY-LITER™ PI 试剂 |
| Sperm Hyliter™ PI | 7402 | 中等精子 HY-LITER™ PI 试剂,用于染色 50、11 mm 孔或 100、8 mm 孔 |
| Sperm Hyliter™ PI | 7403 | 大精子 HY-LITER™ PI 试剂,用于染色 150、11 mm 孔或 300、8 mm 孔 |
| Sperm Hyliter™ PI | 7402-SOS | SPERM HY-LITER™ PI SOS - 带国际 DTT 的新型溶液染色试剂盒,染色 50 载玻片 |
| Sperm Hyliter™ PI | 7403-SOS | SPERM HY-LITER™ SOS - 新型溶液染色试剂盒,带国际 DTT,染色 150 个样品 |
| Sperm Hyliter™ | 7126 | 用于染色 26、11 mm 孔或 50、8 mm 孔的小精子 HY-LITER™ 试剂 |
| Sperm Hyliter™ | 7150 | 中等精子 HY-LITTER™ 试剂,用于染色 50, 11 mm 孔或 100, 8 mm 孔 |
| Sperm Hyliter™ | 7250 | 大精子 HY-LITER™ 试剂,用于染色 150、11 mm 孔或 300、8 mm 孔 |
| Sperm Hyliter™ | 7250P | SPERM HY-LITER™ 大号套件,带 DTT,150 个 1x11 mm 孔载玻片和储存盒 |
| RSID™ Urine Field Kits | 4000 | 尿液 5 次检测/试剂盒,含预装尿液缓冲液、拭子、水和移液管 |
| RSID™ Urine Field Kits | 4000-10 | 尿液 10 次检测/试剂盒(同上 - 不包括剪刀或证据信封) |

艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://panagene.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸

艾美捷科技代理代理MYOCEA品牌产品。
MYOCEA是一家专注于肌肉生物学和细胞培养技术的公司,致力于为科研和工业应用提供创新的肌肉细胞模型和相关产品。MYOCEA 以其独特的MyoCells™技术平台而闻名,该平台能够生成高度功能化的肌肉细胞,广泛应用于药物开发、毒理学测试、食品科学和再生医学等领域。MyoCells™技术平台能够生成与体内肌肉细胞高度相似的体外模型,为研究肌肉生物学和相关疾病提供了强大的工具。MYOCEA主要产品和技术包括:
(1)MyoCells™ 平台
MyoCells™ 肌肉细胞,高度功能化的肌肉细胞,具有与体内肌肉相似的生理特性。
MyoCells™ 培养基,专为肌肉细胞优化,支持细胞生长和功能维持。
MyoCells™ 试剂盒,包含细胞、培养基和实验指南,方便用户快速开展实验。
(2)药物开发工具
肌肉毒性测试,用于评估药物对肌肉细胞的毒性。
肌肉功能分析,提供高灵敏度的收缩性和代谢活性检测工具。
个性化药物筛选,基于患者来源的肌肉细胞模型,支持个性化医疗研究。
(3)食品科学应用
细胞培养肉研究,提供高质量的肌肉细胞,用于细胞培养肉开发。
食品添加剂测试,用于评估食品添加剂对肌肉细胞的影响。
(4)再生医学工具
肌肉再生研究,提供肌肉细胞模型,用于研究肌肉再生和修复机制。
组织工程,支持肌肉组织工程和生物材料开发。
(5)定制服务
定制肌肉细胞模型,根据客户需求开发特定的肌肉细胞模型。
合同研究服务(CRO),提供从实验设计到数据分析的全流程服务。

艾美捷科技代理Gene Tools品牌
Gene Tools是一家生产和销售Morpholino Anti-sense oligos(反义寡核苷酸)的公司,其产品专门用于基因调控的科学研究和药物开发。Gene Tools公司由多位资深科学家组成,为全球客户提供免费的技术咨询和Morpholino 序列设计服务。 Morpholino作为基因调控研究的最佳工具,已被广泛用于:阻断靶mRNA 翻译 (下调基因);诱导RNA选择性剪接 (下调或上调基因);阻断 miRNA;阻断病毒 RNA;阻断 non-coding RNA。
▍Morpholino介绍
Morpholino属于第三代反义寡核苷酸,主要通过阻断蛋白质翻译过程而达到抑制目标基因功能的作用,目前已经广泛用于发育生物学和细胞学实验中,并取得了非常好的实验效果。
Morpholino以吗啉环类似物为基本骨架,这种独特的结构特性使得Morpholino 具有以下几个特点:
● 与其他类型的反义寡核苷酸相比,Morpholino 能更好地抵抗核酸酶的作用;
● Morpholino 与靶序列结合后通过空间位阻效应发挥作用, 不激活RNaseH,不引起目标基因mRNA 的降解 ;
● 针对翻译起始位点区设计的Morpholino 用于抑制蛋白质的翻译,针对 pre-mRNA 剪切位点区设计的Morpholino 可影响mRNA 剪切,得到不 同的转录本,可以方便地用于目标基因结构域的突变研究;
● 与靶序列结合能力强,可以渗入mRNA 的二级结构, 并且特异性好。
配合Morpholino 的使用,Gene Tools公司开发了相应的递送系统,可以安全、高效地将Morpholino 输送至胞内,因此,Morpholino 也可以用于遗传学研究和新药靶标的发现以及验证。此外,Morpholino 可以标上荧光基团、亲和标签以及活性反应基团,以供不同的研究需要。

▍Gene Tools公司产品介绍
● Custom Morpholino:可以根据目标基因序列定制设计并合成Morpholino,用于体外细胞实验或某些直接显微注射的模型(如斑马鱼、非洲爪蟾胚胎)。
● Vivo-Morpholino:适用于活体动物模型(小鼠,大鼠,狗,灵长类等),细胞培养,器官培养等。通过特殊的末端修饰,提高了其穿透细胞膜进入组织细胞的能力,使得在成年动物(主要是小鼠、大鼠)中进行系统性基因功能研究成为可能。
● Prepared Control Oligos:根据特定需求合成细胞穿透肽偶联的 Morpholino。适用于活体动物模型(小鼠,大鼠,狗,灵长类等),细胞培养,器官培养等。
| 产品名称 | Short Description | Oligo sequence | SKU |
| Standard Control Oligo | Negative control oligo | CCTCTTACCTCAGTTACAATTTATA | PCO-StandardControl-100 |
| Vivo-Morpholino Standard Control Oligo | Negative Vivo-Morpholino control oligo | CCTCTTACCTCAGTTACAATTTATA | PCO-VivoStandardControl-100 |
| Random Control Oligo 25-N | 25-base random sequence mixture | NNNNNNNNNNNNNNNNNNNNNNNNN | PCO-RandomControl-25N-100 |
| Zebrafish p53 oligo | Danio rerio apoptosis suppression oligo | GCGCCATTGCTTTGCAAGAATTG | PCO-ZebrafishP53-100 |
| Zebrafish Chordin Positive Control Oligo | Danio rerio Chordin positive control oligo | ATCCACAGCAGCCCCTCCATCATCC | PCO-ZebrafishChordin-100-F |
| Clawed Frog Beta Catenin Positive Control Oligo | Xenopus laevis Beta Catenin antisense oligo | TTTCAACCGTTTCCAAAGAACCAGG | PCO-BetaCatenin-100-F |
| Green Fluorescent Protein Positive Control | Translation blocker for GFP target | ACAGCTCCTCGCCCTTGCTCACCAT | PCO-GFPControl-100 |
| Vivo-Morpholino GFP Positive Control | Translation blocker for GFP target (Vivo-Morpholino) | ACAGCTCCTCGCCCTTGCTCACCAT | PCO-VivoGFPControl-100 |
| Fluoresceinated Vivo-Morpholino Std Control | Negative Vivo-Morpholino control oligo with 5'Fluorescein | CCTCTTACCTCAGTTACAATTTATA | PCO-FluorVivoStandardControl-100-F |
● Endo-Porter:为了解决Morpholino在体外培养细胞中摄取效率低的问题,Gene Tools 开发了 Endo-Porter 这种特殊的转染试剂。它通过温和的内吞体逃逸机制帮助Morpholino进入细胞质。

艾美捷科技代理Giotto Biotech品牌。
Giotto Biotech公司是一家专注于核磁共振(NMR)相关技术的意大利生物技术公司。Giotto Biotech Srl是佛罗伦萨大学磁共振中心(CERM)的衍生品或分公司,与佛罗伦萨大学磁共振中心保持着密切的合作关系。Giotto Biotech专注于与核磁共振(NMR)有关的所有技术,致力于为学术和工业研究团体提供高质量的产品和服务。Giotto Biotech公司提供的产品和服务涵盖了多个领域:
(1)生物分子与有机合成:提供生物分子和有机合成相关的产品和服务,满足学术和工业研究的需求。
(2)代谢组学:利用NMR技术进行代谢组学研究,为客户提供代谢产物的定性和定量分析服务。
(3)NMR访问与信息技术:提供NMR仪器的访问权限以及相关的信息技术产品和服务,支持客户的NMR研究。
(4)定制生产服务:拥有大量的蛋白质表达产物,可以通过在大肠杆菌中的表达产生蛋白质。同时,公司还提供定制生产服务,包括重组蛋白质、肽类、有机分子和抗体等同位素标记的定制生产。
Giotto Biotech公司拥有丰富的蛋白质库,包括多种基质金属蛋白酶、S100蛋白质、Fe-S蛋白质等,可以满足客户在蛋白质研究方面的需求。Giotto Biotech注重产品质量和服务质量,通过质谱和NMR光谱等手段保证产品的纯度和质量,产品和服务广泛应用于生物医学、制药、农业和食品等多个领域。在生物医学领域,公司提供的代谢组学服务可以帮助研究人员进行疾病指纹图谱的构建和生物标志物的发现;在制药领域,公司可以利用NMR技术进行药物毒性的预测和药物作用机制的分析;在农业和食品领域,公司可以提供食品成分的分析和质量控制等服务。
<< " data-original="http://panagene.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Giotto Biotech品牌"> 艾美捷科技代理Giotto Biotech品牌
艾美捷科技代理BioLab Assays 品牌。
BioLab Assays Ltd.开发、制造和销售创新和原创的即用ELISA(酶联免疫吸附测定)试剂盒。其产品组合包括固相96孔ELISA,设计用于定量测量细胞因子、急性反应物蛋白或趋化因子,并针对血清、血浆、尿液、唾液或脑脊液样品进行了优化。BioLab Assays公司产品涵盖以下领域:肥胖,IR,代谢综合征,糖尿病,肾脏疾病,肺部疾病,动物护理和研究,骨代谢,炎症和感染。
<BioLab Assays公司提供的产品和服务主要包括:
(1)即用型ELISA试剂盒:这是公司的核心产品,用于定量测量各种生物标志物,如细胞因子、急性反应物蛋白、趋化因子等。
(2)定制免疫检测开发:公司还提供定制免疫检测开发服务,以满足客户的特定需求。
(3)合同制造服务:除了自主开发和销售产品外,BioLab Assays公司还提供合同制造服务,为其他公司提供高质量的免疫检测产品。

艾美捷科技代理法国Solabia品牌酵母粉和蛋白胨。
Solabia Group 是一家法国生物技术公司,专注于开发和生产天然活性成分、功能性原料和生物技术产品。其产品广泛应用于化妆品、营养保健品、制药和生物技术领域。Solabia 的酵母粉和蛋白胨是其在生物技术领域的重要产品,主要用于微生物培养、发酵工艺和科学研究。Solabia提供多种类蛋白胨和酵母粉,包括:大豆蛋白胨、胰蛋白胨、酸水解酪蛋白、酵母粉、小麦/蚕豆/羽扇豆/土豆/豌豆蛋白胨等。
< " data-original="http://panagene.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理法国Solabia品牌酵母粉和蛋白胨"> 艾美捷科技代理法国Solabia品牌酵母粉和蛋白胨
地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:13212737804
传真:18771997407
邮箱:sales@amyjet.com
0.1324